PRAX Quote, Financials, Valuation and Earnings

BioXcel Therapeutics has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -4317.86%. Praxis Precision Medicines's return on equity of -59.11% beat BioXcel Therapeutics's return on equity of --.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 153.35%. On the other hand BioXcel Therapeutics has an analysts' consensus of $48.00 which suggests that it could grow by 3967.8%. Given that BioXcel Therapeutics has higher upside potential than Praxis Precision Medicines, analysts believe BioXcel Therapeutics is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison BioXcel Therapeutics has a beta of -0.122, suggesting its less volatile than the S&P 500 by 112.234%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. BioXcel Therapeutics offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. BioXcel Therapeutics pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than BioXcel Therapeutics quarterly revenues of $168K. Praxis Precision Medicines's net income of -$69.3M is lower than BioXcel Therapeutics's net income of -$7.3M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while BioXcel Therapeutics's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.75x versus 2.08x for BioXcel Therapeutics. Usually stocks with elevated PS ratios are considered overvalued.

CEL-SCI has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of --. Praxis Precision Medicines's return on equity of -59.11% beat CEL-SCI's return on equity of --.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 153.35%. On the other hand CEL-SCI has an analysts' consensus of $8.00 which suggests that it could grow by 11329.71%. Given that CEL-SCI has higher upside potential than Praxis Precision Medicines, analysts believe CEL-SCI is more attractive than Praxis Precision Medicines.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI has a beta of 0.271, suggesting its less volatile than the S&P 500 by 72.891%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. CEL-SCI pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are larger than CEL-SCI quarterly revenues of --. Praxis Precision Medicines's net income of -$69.3M is lower than CEL-SCI's net income of -$6.6M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while CEL-SCI's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.75x versus -- for CEL-SCI. Usually stocks with elevated PS ratios are considered overvalued.

DocGo has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -9.79%. Praxis Precision Medicines's return on equity of -59.11% beat DocGo's return on equity of -0.2%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 153.35%. On the other hand DocGo has an analysts' consensus of $3.05 which suggests that it could grow by 114.78%. Given that Praxis Precision Medicines has higher upside potential than DocGo, analysts believe Praxis Precision Medicines is more attractive than DocGo.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison DocGo has a beta of 0.000, suggesting its less volatile than the S&P 500 by 100%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. DocGo offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. DocGo pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than DocGo quarterly revenues of $96M. Praxis Precision Medicines's net income of -$69.3M is lower than DocGo's net income of -$9.4M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while DocGo's PE ratio is 8.24x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.75x versus 0.29x for DocGo. Usually stocks with elevated PS ratios are considered overvalued.

Owens & Minor has a net margin of -786.27% compared to Praxis Precision Medicines's net margin of -0.95%. Praxis Precision Medicines's return on equity of -59.11% beat Owens & Minor's return on equity of -48.56%.

Praxis Precision Medicines has a consensus price target of $97.67, signalling upside risk potential of 153.35%. On the other hand Owens & Minor has an analysts' consensus of $9.25 which suggests that it could grow by 47.73%. Given that Praxis Precision Medicines has higher upside potential than Owens & Minor, analysts believe Praxis Precision Medicines is more attractive than Owens & Minor.

Praxis Precision Medicines has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Owens & Minor has a beta of 1.306, suggesting its more volatile than the S&P 500 by 30.598%.

Praxis Precision Medicines has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Owens & Minor offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Praxis Precision Medicines pays -- of its earnings as a dividend. Owens & Minor pays out -- of its earnings as a dividend.

Praxis Precision Medicines quarterly revenues are $7.5M, which are smaller than Owens & Minor quarterly revenues of $2.6B. Praxis Precision Medicines's net income of -$69.3M is lower than Owens & Minor's net income of -$25M. Notably, Praxis Precision Medicines's price-to-earnings ratio is -- while Owens & Minor's PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Praxis Precision Medicines is 88.75x versus 0.05x for Owens & Minor. Usually stocks with elevated PS ratios are considered overvalued.